SCHEMBL23714709

SCHEMBL23714709

CCc1cc2c(Br)cccc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
HRH4 Q9H3N8 1/20 0.41
AHR P35869 1/20 0.41
KIF11 P52732 1/20 0.40
FLT3 P36888 1/20 0.39
ITK Q08881 1/20 0.39
DAO P14920 1/20 0.39
DDO Q99489 1/20 0.39
NOS1 P29475 1/20 0.39
AXL P30530 1/20 0.39
RHEB Q15382 3/20 0.38
MTNR1A P48039 4/20 0.38
MTNR1B P49286 4/20 0.38
CTSV O60911 2/20 0.36
CTSL P07711 2/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30096998 0.81 RHEB (0.55) HRH4AHRFLT3ITKRHEB
SCHEMBL23706115 0.81 RHEB (0.55) HRH4AHRFLT3ITKRHEB
SCHEMBL31534617 0.81 LOXL2 (0.52) HRH4AHRFLT3ITKNOS1
SCHEMBL20125059 0.79 DAO (0.60) PARP1KIF11DAODDOMTNR1A
SCHEMBL5917425 0.78 DAO (0.49) PARP1HRH4KIF11FLT3DAO
SCHEMBL5769848 0.78 DAO (0.50) PARP1HRH4KIF11DAODDO
SCHEMBL17345632 0.78 DAO (0.49) PARP1HRH4KIF11FLT3DAO
SCHEMBL30480858 0.77 DAO (0.54) PARP1HRH4FLT3DAODDO
SCHEMBL28577623 0.76 FLT3 (0.45) HRH4FLT3RHEBMTNR1AMTNR1B
SCHEMBL24453539 0.75 NR3C1 (0.45) PARP1KIF11DAODDOMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115297861-A Compound and use thereof 福宏治疗公司 2022-11-04 CN disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
CN-110272323-A A kind of microwave assisted synthesizing method of ethylation reaction 广东石油化工学院 2019-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB PARP1 491/4885HRH4 3580/4885AHR 2619/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB PARP1 491/4885HRH4 3580/4885AHR 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.